Literature DB >> 12354837

Surgical management of hepatocellular carcinoma: resection and ablation.

Michael A Choti1.   

Abstract

In this article, the author reviews the recent advances in the surgical management of hepatocellular carcinoma (HCC). Partial hepatic resection or, in some instances, liver transplantation provides the best chance for cure. Risk of perioperative mortality after partial hepatectomy is less than 5% in most experienced centers. Careful preoperative assessment of hepatic function is important to reduce the risk of postoperative liver failure after liver resection. Long-term outcomes after resection are comparable to those with liver transplantation, with reported 5-year survival rates of 25%-50%. Although limited controlled comparative studies exist, surgical and nonsurgical local ablative therapies, including ethanol and radiofrequency ablation, may result in survival benefit.

Entities:  

Mesh:

Year:  2002        PMID: 12354837     DOI: 10.1016/s1051-0443(07)61787-4

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  9 in total

1.  Three-dimensional ultrasound-guided robotic needle placement: an experimental evaluation.

Authors:  Emad M Boctor; Michael A Choti; Everette C Burdette; Robert J Webster Iii
Journal:  Int J Med Robot       Date:  2008-06       Impact factor: 2.547

2.  Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres.

Authors:  Tobias F Jakobs; Ralf-T Hoffmann; Gabriele Poepperl; Anna Schmitz; Jürgen Lutz; Walter Koch; Klaus Tatsch; Andreas Lubiensky; Maximilian F Reiser; Thomas Helmberger
Journal:  Eur Radiol       Date:  2006-12-06       Impact factor: 5.315

3.  Patient selection for surgical management of primary and metastatic liver cancers: current perspectives.

Authors:  J Alexander Palesty; Mazin Al-Kasspooles; John F Gibbs
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

4.  Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series.

Authors:  Dongil Choi; Hyo K Lim; Hyunchul Rhim; Young-Sun Kim; Won Jae Lee; Seung Woon Paik; Kwang Cheol Koh; Joon Hyoek Lee; Moon Seok Choi; Byung Chul Yoo
Journal:  Eur Radiol       Date:  2006-11-09       Impact factor: 5.315

5.  Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes.

Authors:  Makoto Ogihara; Linda L Wong; Junji Machi
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

6.  Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver.

Authors:  Marco Vivarelli; Alfredo Guglielmi; Andrea Ruzzenente; Alessandro Cucchetti; Roberto Bellusci; Claudio Cordiano; Antonino Cavallari
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

Review 7.  [Percutaneous radiofrequency ablation of liver cell carcinoma: a current overview].

Authors:  J Kettenbach; M Blum; E Kilanowicz; S M Schwaighofer; J Lammer
Journal:  Radiologe       Date:  2004-04       Impact factor: 0.635

8.  Comparison of the safety and efficacy of hepatic resection and radiofrequency ablation in the treatment of single small hepatocellular carcinoma: systematic review and meta-analysis.

Authors:  Ke Wang; Rui Wang; Siqin Liu; Guoqing Peng; Huan Yu; Xiaomei Wang
Journal:  Transl Cancer Res       Date:  2022-03       Impact factor: 1.241

Review 9.  Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines.

Authors:  Ayman A Abdo; Mazen Hassanain; AbdulRahman AlJumah; Ashwaq Al Olayan; Faisal M Sanai; Hamad A Alsuhaibani; Huda Abdulkareem; Khalid Abdallah; Mohammad AlMuaikeel; Mohammad Al Saghier; Mohammad Babatin; Monther Kabbani; Shouki Bazarbashi; Peter Metrakos; Jordi Bruix
Journal:  Ann Saudi Med       Date:  2012 Mar-Apr       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.